文献速递垂体与肾上腺疾病糖尿病

散发性神经内分泌肿瘤与MEN1患者中的ARMC5基因改变

ARMC5 Alterations in Patients With Sporadic Neuroendocrine Tumors and Multiple Endocrine Neoplasia Type 1 (MEN1).
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究对111例散发性神经内分泌肿瘤(spNET)或MEN1患者进行ARMC5胚系变异筛查,发现68.4%携带至少一种变异,肿瘤中常见16p染色体杂合性缺失与ARMC5变异共存,且MEN1相关肿瘤中双等位基因失活更普遍,提示ARMC5可能修饰spNET和MEN1表型。

要点

  • spNET和MEN1患者中ARMC5胚系变异常见,携带率为68.4%。
  • ARMC5可能作为修饰基因影响spNET和MEN1的肿瘤表型。

核心结论

  • ARMC5胚系变异在spNET和MEN1患者中常见,可能通过单倍剂量不足或双等位基因失活参与肿瘤表型修饰。

研究设计与样本

  • 共纳入111例患者(94例spNET,17例MEN1),筛查ARMC5胚系改变。
  • 用免疫组化评估ARMC5和MEN1表达。

主要发现

  • 76/111(68.4%)患者携带16种不同的ARMC5胚系变异,其中2种预测为有害。
  • ARMC5变异患病率在有无MEN1相关肾上腺病变的患者间无差异。
  • 23/34(67.6%)肿瘤同时存在16p染色体杂合性缺失(LOH)和ARMC5胚系变异,其中7/23(30.4%)导致ARMC5双等位基因失活。

临床怎么用

  • 对于spNET或MEN1患者,可考虑ARMC5胚系检测以评估肿瘤易感性。
  • ARMC5变异可能影响肾上腺病变及肿瘤表型,需结合影像学和生化监测。

局限性

  • 样本量有限,尤其MEN1患者仅17例。
  • ARMC5变异的功能后果未通过体外实验验证。
  • 未评估ARMC5变异对临床结局的长期影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Adrenal lesions are frequent among patients with sporadic neuroendocrine tumors (spNETs) or multiple endocrine neoplasia type 1 (MEN1). Armadillo repeat-containing 5 (ARMC5)-inactivating variants cause adrenal tumors and possibly other neoplasms. OBJECTIVE: The objective of this work is to investigate a large cohort spNETs or MEN1 patients for changes in the ARMC5 gene. PATIENTS AND METHODS: A total of 111 patients, 94 with spNET and 17 with MEN1, were screened for ARMC5 germline alterations. Thirty-six tumors (18 spNETs and 18 MEN1 related) were collected from 20 patients. Blood and tumor DNA samples were genotyped using Sanger sequencing and microsatellite markers for chromosomes. ARMC5 and MEN1 expression were assessed by immunohistochemistry. RESULTS: In 76 of 111 (68.4%) patients, we identified 16 different ARMC5 germline variants, 2 predicted as damaging. There were no differences in the prevalence of ARMC5 variants depending on the presence of MEN1-related adrenal lesions. Loss of heterozygosity (LOH) at chromosome 16p and ARMC5 germline variants were present together in 23 or 34 (67.6%) tumors; in 7 of 23 (30.4%) their presence led to biallelic inactivation of the ARMC5 gene. The latter was more prevalent in MEN1-related tumors than in spNETs (88.9% vs 38.9%; P = .005). LOH at the chromosome 16p (ARMC5) and 11q (MEN1) loci coexisted in 16/18 MEN1-related tumors, which also expressed lower ARMC5 (P = .02) and MEN1 (P = .01) proteins compared to peritumorous tissues. CONCLUSION: Germline ARMC5 variants are common among spNET and MEN1 patients. ARMC5 haploinsufficiency or biallelic inactivation in spNETs and MEN1-related tumors suggests that ARMC5 may have a role in modifying the phenotype of patients with spNETs and/or MEN1 beyond its known role in macronodular adrenocortical hyperplasia.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Damjanovic SS, Antic JA, Elezovic-Kovacevic VI, et al. ARMC5 Alterations in Patients With Sporadic Neuroendocrine Tumors and Multiple Endocrine Neoplasia Type 1 (MEN1). J Clin Endocrinol Metab. 2020. PMID: 32901291. doi:10.1210/clinem/dgaa631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。